• Alcon entered a non-exclusive collaboration with RxSight to develop adjustable presbyopia-correcting intraocular lenses for cataract patients.
• Program combines RxSight’s post-operative light-adjustable technology with Alcon’s PCIOL optical designs to fine-tune outcomes after surgery.
• RxSight will receive a USD 60 million upfront payment.
• RxSight could earn up to USD 140 million in additional development and regulatory milestone payments.
• Alcon will lead global commercialization; RxSight will handle development, manufacturing, royalty-bearing supply on net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alcon AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20260702035569) on July 06, 2026, and is solely responsible for the information contained therein.